烧伤患者中的多重耐药菌:终结还是新的开始
本综述检视烧伤患者多重耐药菌(MDROs)的现有治疗选择,涵盖新型抗生素(如Eravacycline与Plazomicin)及非抗生素疗法(如噬菌体与纳米颗粒),并展望其日益流行带来的未来挑战。未来研究应聚焦不同治疗模式的长期疗效、成本效益与体内疗效,并探索益生菌、低频磁场等替代疗法,开发快速精准的诊断监测工具。
要点
- 烧伤患者感染管理因多重耐药菌(MDROs)流行而更具挑战。
- 治疗选择包括新型抗生素Eravacycline、Plazomicin及噬菌体、纳米颗粒等非抗生素疗法。
- 未来需评估各疗法的长期疗效、成本效益与体内疗效,并开发快速诊断监测工具。
核心结论
- 烧伤护理中多重耐药菌(MDROs)的出现既是挑战,也是感染创新与新型治疗的新起点。
研究设计与样本
- 综述,检视烧伤患者多重耐药菌(MDROs)的可用治疗选择并展望未来挑战。
主要发现
- 综述涵盖新型抗生素如Eravacycline与Plazomicin,以及噬菌体和纳米颗粒等非抗生素疗法。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Infections are a major cause of morbidity and mortality in burn patients, and the rise of multidrug-resistant organisms (MDROs) has made it more challenging to manage and prevent infections. This review examines the available treatment options for MDROs in burn patients and anticipates the future challenges posed by their increasing prevalence. The review covers new antibiotics, such as Eravacycline and Plazomicin, as well as non-antibiotic therapies, such as bacteriophages and nanoparticles. Future research should focus on examining the long-term efficacy, cost-effectiveness, and in vivo efficacy of different treatment modalities. The potential of alternative therapies, such as probiotics and low-frequency magnetic fields, should also be explored. Accurate and rapid diagnostic and monitoring tools for detecting MDROs in burn patients should be developed. The emergence of MDROs in burn care is a challenge and a new beginning in infection innovation and novel treatments.
引用
- Hagiga A, Dheansa B. Multi-resistant organisms in burn patients: an end or a new beginning. Burns. 2024. PMID: 38472000. doi:10.1016/j.burns.2024.02.024
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。